NorthWest Biotherapeutics Inc (NWBO)

[hankmanhub]

Paying generic companies to keep generic competitors off the market is not right but it does not compare to what you are claiming, which would be keeping science innovation off the market.

No that is not what I am suggesting. I think that they want to position themselves to get a piece of the pie and themselves become involved in bringing the new technology to market. Not to keep it off the market - and in doing so perhaps delay it a little while their revenue producing chemo stays on the market a little longer.

If you think about it, a day ;like today that say ends with a volume of about 14 M shares traded with perhaps 10 M of them shorted. If say they lose 10 cents on every short that passes in and out of their hand in the shorting process, then today's short will have only cost them about $1 M - that is chump change for them, and a cost of achieving theit ultimate aims.